Bianca Z Kinnear1, Natasha A Lannin2, Anne Cusick3, Lisa A Harvey4, Barry Rawicki5. 1. B.Z. Kinnear, BAppSc(OT), Faculty of Social Sciences, University of Wollongong, Wollongong, New South Wales, Australia. Mailing address: School of Health and Society, Illawarra Health & Medical Research Institute, University of Wollongong, Northfields Avenue, Wollongong, New South Wales, 2522 Australia. bkinnear@hammond.com.au biancakinnear@hotmail.com. 2. N.A. Lannin, PhD, BSc(OT), GradDip, Department of Occupational Therapy, La Trobe University, and Occupational Therapy Department, Alfred Health Melbourne, Victoria, Australia. 3. A. Cusick, PhD, BAppSc(OT), MA(Psych), MA(Interdisc Stud), PhD, Faculty of Social Sciences, University of Wollongong. 4. L.A. Harvey, BAppSc, GradDipAppSc(ExSpSc), MAppSc, PhD, Rehabilitation Studies Unit, Kolling Institute, Sydney Medical School/Northern, University of Sydney, New South Wales, Australia. 5. B. Rawicki, MB, BS, FAFRM, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Botulinum toxin A (BoNT-A) injections are increasingly used to treat muscle spasticity and are often complemented by adjunctive rehabilitation therapies; however, little is known about the effect of therapy after injection. PURPOSE: The aim of this study was to identify and summarize evidence on rehabilitation therapies used after BoNT-A injections to improve motor function in adults with neurological impairments. DATA SOURCES: Searches were conducted in PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, National Research Register, metaRegistry of Controlled Trials, PEDro, and OTseeker. STUDY SELECTION: Randomized and quasi-randomized controlled trials were considered for inclusion. Participants with neurological impairments received BoNT-A to treat focal spasticity in limbs, with rehabilitation interventions provided to experimental groups only. Primary outcome measures were joint mobility, function of the affected limb, and spasticity. Eleven studies with 234 participants, most of whom had stroke, were included in the review. DATA EXTRACTION: Two reviewers extracted study details and data. DATA SYNTHESIS: Methodological quality was rated using the PEDro scale. Both fixed-effects and random-effects models were used to calculate effect size. RESULTS: Studies were of variable quality: 3 were poor (PEDro score 1 to 4), and 8 were moderate (PEDro score 6 to 7). No study investigated effects for longer than 24 weeks (6 months). Included trials presented 9 therapy types, including ergometer cycling, electrical stimulation, stretch (casting, splinting, taping, or manual or exercise-induced stretch), constraint-induced movement therapy, task-specific motor training, and exercise programs. Statistical findings suggest that combined therapy and BoNT-A is slightly more effective than BoNT-A alone. CONCLUSION: Evidence relating to impact of adjunct therapy is available, but the heterogeneity of studies limits the opportunity to demonstrate overall impact. Researchers need to consider the benefits of greater consistency in study approaches and measures so that meaningful evaluations of overall adjunct therapy effects can be made.
BACKGROUND: Botulinum toxin A (BoNT-A) injections are increasingly used to treat muscle spasticity and are often complemented by adjunctive rehabilitation therapies; however, little is known about the effect of therapy after injection. PURPOSE: The aim of this study was to identify and summarize evidence on rehabilitation therapies used after BoNT-A injections to improve motor function in adults with neurological impairments. DATA SOURCES: Searches were conducted in PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, National Research Register, metaRegistry of Controlled Trials, PEDro, and OTseeker. STUDY SELECTION: Randomized and quasi-randomized controlled trials were considered for inclusion. Participants with neurological impairments received BoNT-A to treat focal spasticity in limbs, with rehabilitation interventions provided to experimental groups only. Primary outcome measures were joint mobility, function of the affected limb, and spasticity. Eleven studies with 234 participants, most of whom had stroke, were included in the review. DATA EXTRACTION: Two reviewers extracted study details and data. DATA SYNTHESIS: Methodological quality was rated using the PEDro scale. Both fixed-effects and random-effects models were used to calculate effect size. RESULTS: Studies were of variable quality: 3 were poor (PEDro score 1 to 4), and 8 were moderate (PEDro score 6 to 7). No study investigated effects for longer than 24 weeks (6 months). Included trials presented 9 therapy types, including ergometer cycling, electrical stimulation, stretch (casting, splinting, taping, or manual or exercise-induced stretch), constraint-induced movement therapy, task-specific motor training, and exercise programs. Statistical findings suggest that combined therapy and BoNT-A is slightly more effective than BoNT-A alone. CONCLUSION: Evidence relating to impact of adjunct therapy is available, but the heterogeneity of studies limits the opportunity to demonstrate overall impact. Researchers need to consider the benefits of greater consistency in study approaches and measures so that meaningful evaluations of overall adjunct therapy effects can be made.
Authors: Jean-Michel Gracies; Michael O'Dell; Michele Vecchio; Peter Hedera; Serdar Kocer; Monika Rudzinska-Bar; Bruce Rubin; Sofiya L Timerbaeva; Anna Lusakowska; François Constant Boyer; Anne-Sophie Grandoulier; Claire Vilain; Philippe Picaut Journal: Muscle Nerve Date: 2017-08-13 Impact factor: 3.217
Authors: Natasha A Lannin; Louise Ada; Coralie English; Julie Ratcliffe; Steven G Faux; Mithu Palit; Senen Gonzalez; John Olver; Ian Cameron; Maria Crotty Journal: Stroke Date: 2019-12-09 Impact factor: 7.914
Authors: Raymond L Rosales; Jovita Balcaitiene; Hugues Berard; Pascal Maisonobe; Khean Jin Goh; Witsanu Kumthornthip; Mazlina Mazlan; Lydia Abdul Latif; Mary Mildred D Delos Santos; Chayaporn Chotiyarnwong; Phakamas Tanvijit; Odessa Nuez; Keng He Kong Journal: Toxins (Basel) Date: 2018-06-21 Impact factor: 4.546